Lexaria Reaches Patent Milestone - 50 Patents Now Granted Worldwide

New patents received for the treatment of epilepsy and for the sublingual delivery of nicotine
KELOWNA, BC / ACCESS Newswire / June 23, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the 'Company' or 'Lexaria'), a global innovator in drug delivery platforms, is pleased to announce that it has received 2 new international patents. This now brings Lexaria's total worldwide patent portfolio to 50.
'We are pleased to announce the addition of these patents as we continue to execute on our strategy to broaden Lexaria's patent portfolio. We believe that this not only increases our likelihood of entering into commercial deals within the pharmaceutical industry, but that it also serves as an important building block for establishing and protecting long-term value for our shareholders and all stakeholders,' said Rich Christopher, CEO of Lexaria. 'The achievement of 50 worldwide patents marks the accomplishment of a milestone that had been envisioned by the Company's management for over a decade.'
Lexaria has been granted a new patent in Australia within its patent family #24, Compositions and Methods for Treating Epilepsy. This broadens Lexaria's intellectual property protection for the use of its DehydraTECH™ enhanced processing technology related to the treatment of epilepsy outside of the USA, where a strong patent portfolio of 6 existing patents has already been built. This new patent will expire in 2044.
Lexaria has also been granted a new patent in Japan within its patent family #20, Compositions and Methods for Sublingual Delivery of Nicotine. This patent joins already-existing patents within the same family in both the USA and Canada. This new patent will expire in 2043.
The epilepsy drug market was US$9.5 billion in 2023 and is expected to reach sales of over $15 billion by 2032. Approximately 50 million people in the US alone are affected by epilepsy.
The global retail oral nicotine market was valued at US$5.5 billion in 2023 and is expected to grow at 26%/yr until at least 2030, with additional revenue generated within the medically-prescribed market. The nicotine pouch market alone - where DehydraTECH™ has demonstrated absorption benefits in earlier studies - is expected to reach US$25.4 billion in revenue by 2030. Altria Ventures Inc. the 16.67% shareholder of Lexaria Nicotine LLC, holds a non-exclusive license to the use of DehydraTECH with nicotine products.
About Lexaria Bioscience Corp. & DehydraTECH
DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way active pharmaceutical ingredients enter the bloodstream through oral delivery. Lexaria has developed and investigated DehydraTECH with a variety of beneficial molecules in oral formats. DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption and has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 50 patents granted and additional patents pending worldwide. For more information, please visit www.lexariabioscience.com.
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as 'anticipate,' 'if,' 'believe,' 'plan,' 'estimate,' 'expect,' 'intend,' 'may,' 'could,' 'should,' 'will,' and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the company relating the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.
INVESTOR CONTACT:
George Jurcic - Head of Investor Relations
[email protected]
Phone: 250-765-6424, ext 202
SOURCE: Lexaria Bioscience Corp.
press release

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Forbes

37 minutes ago

• Forbes

How A New Wave Of Defence Spending Is Helping Climate Innovators

Ally LaTourelle Whitney, Founder of the Government Affairs Accelerator Why National Security Spending Might Be the Unexpected Ally of Climate Tech As global powers escalate military spending, climate advocates are sounding the alarm: could this defence-first posture stall momentum for green innovation? Not necessarily, argues Ally LaTourelle Whitney, founder of the Government Affairs Accelerator. For her, the answer isn't retreat — it's realignment. 'National security and sustainability are no longer separate conversations,' she says. 'What we're seeing is not a full redirection of funding, but a diversification of portfolios.' And the numbers suggest just how serious the global defence pivot has become. In 2023, the United States passed a record $858 billion defence budget. Germany committed €500 billion to military and infrastructure upgrades. Japan approved its largest postwar defence package. With the war in Ukraine and broader geopolitical tensions continuing to unsettle global markets, defence spending is surging. But LaTourelle Whitney — who also advises America 2030, a $50 million growth-stage fund investing in dual-use technologies — sees a deeper opportunity. Technologies that address both security and climate needs are gaining traction, and the once-clear line between the two sectors is blurring fast. A trained lawyer with experience spanning public policy, finance, and science, LaTourelle Whitney has long operated across sectors. Today, she's at the forefront of a new wave of investors backing 'dual-use' innovation — technologies that serve both military and civilian purposes. 'Lightweight composites, autonomous systems, low-emission fuels — these aren't just military tech,' she explains. 'They're also the building blocks of sustainable infrastructure.' Whitney points out that many modern defence innovations, by necessity, are greener than their predecessors. 'Defence tech is lightweight, electric, reusable — and increasingly dual-use. Consider field-deployable solar panels or autonomous drones designed to reduce fuel-heavy operations. These are defence-first, but they're also climate-supportive.' The U.S., EU, and Asia have been increasing defence budgets while simultaneously issuing mandates for greener military operations — from logistics to procurement. These dual pressures are accelerating the convergence of sustainability and security in innovation. Climate tech is now intertwined with strategic concerns like energy independence and infrastructure resilience. A 2022 report by the International Military Council on Climate and Security called climate change a 'threat multiplier,' exacerbating everything from conflict and migration to economic instability. 'As defence tech becomes more sustainability-conscious, there's growing legitimacy for climate considerations within historically conservative procurement channels,' says LaTourelle Whitney. Examples of this shift are already emerging. The Pentagon has issued calls for field-deployable solar panels and autonomous systems to reduce reliance on vulnerable fuel supply chains. NATO's Defence Innovation Accelerator for the North Atlantic (DIANA), launched in 2023, is funding startups that deliver both operational efficiency and environmental value — from robotics to energy-generating textiles. Meanwhile, companies like Crusoe — which captures flare gas from oil fields and converts it into power for data centres — are demonstrating how climate solutions can have direct applications for edge computing and battlefield energy needs. 'There's a new generation of investors who no longer see sustainability and security as separate lanes,' says LaTourelle Whitney. 'They're thinking holistically — about how technology reduces conflict risk, resource dependence, and geopolitical instability. That's fuelling support for what some now call 'peace tech.'' Despite continued growth in climate tech investment, the capital is shifting toward solutions that serve infrastructure, resilience, and supply chain security. 'Pure-play consumer green tech may feel the squeeze,' LaTourelle Whitney cautions. 'Especially if it lacks ties to critical systems.' Her advice to climate-focused founders? Speak the language of strategic value. 'Can your technology operate off-grid? Does it reduce reliance on foreign-sourced materials? Can it serve disaster zones or conflict environments? If yes, you've got a compelling pitch.' She also encourages climate tech entrepreneurs to explore non-traditional funding paths. Agencies like DARPA or NATO's DIANA, public-private partnerships, and government procurement programmes offer alternatives to venture capital that may be more aligned with the moment. 'Don't just think VC,' she adds. 'Think procurement, think policy, think long-term geopolitical relevance.' The strategic pivot toward dual-purpose technology is already taking hold in national policy. The war in Ukraine, pandemic-era supply chain shocks, and rising concerns over technological sovereignty have pushed governments to reconsider their priorities. 'We're seeing a real shift — mandates for greener defence logistics, sustainable materials like biobased nylons, and remote technologies that support humanitarian and military operations alike,' LaTourelle Whitney says. And climate tech is well-positioned — if it adapts. 'Being green won't be enough,' she concludes. 'But being green, resilient, and strategically relevant? That's a winning formula.'

Bloomberg

an hour ago

• Bloomberg

Tokio Marine Hunts for Deals Abroad, Sees Room for Growth in US

Tokio Marine Holdings Inc. sees scope for further expansion in the US as Japan's largest property-and-casualty insurer explores acquisition opportunities around the world, its new chief executive officer said. 'We want to expand in countries other than the US for geographic diversity, but the US non-life insurance market is far bigger than others,' Masahiro Koike said in an interview. 'So we don't have to worry too much about being overweight there.'

Bloomberg

an hour ago

• Bloomberg

Wolfspeed Plans Bankruptcy After Clinching Deal With Creditors

By , Jonathan Randles, and Steven Church Save Wolfspeed Inc. is planning to file for bankruptcy by July 1 with a deal to slash its debt by about $4.6 billion and hand over control to convertible noteholders. The chipmaker, caught in President Donald Trump's push to reshape Biden-era tech subsidies, said late Sunday it reached a restructuring agreement with a majority of its creditors and Renesas Electronics Corp., a major customer based in Japan, to cut its debt by 70% and reduce annual interest expenses by 60%.